25.1 C
New York
Tuesday, June 2, 2026

Tag: symptoms

newssourceFORcompanyinformationcontent1marketreleases

Defiance Launches the First Autism-Impact ETF (Ticker: ASD), Donating Profits to Autism Causes *

Defiance Launches the First Autism-Impact ETF (Ticker: ASD), Donating Profits to Autism Causes

Public health notice: Outbreak of Salmonella infections linked to various brands of pistachios and pistachio-containing products

August 15, 2025: Update OTTAWA, ON, Aug. 15, 2025 /CNW/ - This outbreak investigation is ongoing. The public health notice will be updated as the investigation...

Galvanize Announces First Patient Enrolled in the PROPEL Registry Evaluating Aliya® Pulsed Electric Field Ablation for Soft Tissue Lesions

Multicenter Registry Launches to Assess Real-World Outcomes and Clinical Integration of Nonthermal Aliya PEF Ablation REDWOOD CITY, Calif., Aug. 15, 2025 /PRNewswire/ -- Galvanize Therapeutics...

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity.

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years

Aira Health Unveils Innovative Wellness Solutions for Women’s Health

Introducing Aira Health: Thoughtfully Formulated Supplements for Women’s Wellness 
Introducing Aira Health: Thoughtfully Formulated Supplements for Women’s Wellness

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Emmaus Life Sciences Reports Quarterly Financial Results

TORRANCE, Calif., Aug. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell...

Base Molecular Resonance™ Technologies Names Bryan Adams as Chief Marketing Officer

Executive Strategist to Lead Global Brand, Market Growth, and Cross-Vertical Commercialization for Quantum Detection Pioneer STUART, Fla., Aug. 14, 2025 /PRNewswire/ -- Base Molecular Resonance™...

Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic

Ad hoc announcement pursuant to Art. 53 LR

Ron Simon & Associates Files First Raw Milk Lawsuit Against Keely Farms Dairy in Florida After Toddler Falls Ill and Mom Loses 20-Week Old...

ORLANDO, Fla., Aug. 13, 2025 /PRNewswire/ -- The national food poisoning law firm of Ron Simon & Associates, along with Orlando-based Newsome Law, PA, has filed...

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren’s Syndrome in China

YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSymptoms

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers